TC-1734: An orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects

CNS Drug Reviews

Volumn 10, Issue 2, 2004, Pages 147-166

  Gatto, Gregory J ^a   Bohme, G Andrees ^b   Caldwell, William S ^a   Letchworth, Sharon R ^a   Traina, Vincent M ^a   Obinu, M Carmen ^b   Laville, Michel ^b   Reibaud, Michel ^b   Pradier, Laurent ^b   Dunbar, Geoffrey ^a   Bencherif, Merouane ^a  

^a TARGACEPT INC   (United States)

^b SANOFI   (France)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; CNS selectivity; Neuronal nicotinic acetylcholine receptors

Indexed keywords

ANTIDEPRESSANT AGENT; ISPRONICLINE; N METHYL 5 [3 (5 ISOPROPOXYPYRIDINYL)] 4 PENTEN 2 AMINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ADULT; ANIMAL BEHAVIOR; ANIMAL MODEL; ANIMAL TISSUE; AVOIDANCE BEHAVIOR; BINDING AFFINITY; BREATHING RATE; CLINICAL TRIAL; COGNITION; CROSSOVER PROCEDURE; DEGENERATIVE DISEASE; DEMENTIA; DOG; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GLUCOSE TRANSPORT; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; LOCOMOTION; MALE; MAZE TEST; MICRODIALYSIS; MODULATION; MOUSE; NEUROPROTECTION; NONHUMAN; NORMAL HUMAN; OXYGEN TRANSPORT; RAT; RECEPTOR SENSITIVITY; RECOGNITION; REVIEW; SIDE EFFECT; SYNAPTIC TRANSMISSION; WORKING MEMORY;

EID: 3042776739     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2004.tb00010.x     Document Type: Review

References (39)

1. Akaike A. Tamura Y. Yokaota T. Shimohama S. Kimura J. Nicotine induce protection of cultured cortical neurones against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res 1994;644: 181-187.
2. Arendash GW. Sanberg PR, Sengstock GJ. Nicotine enhances the learning and memory of aged rats. Pharmacol Biochem Behav 1995;52:517-523.
3. Arneric SP, Sullivan JP, Briggs CA, et al. Preclinical phannacology of ABT-418: A prototypical cholinergic channel activator for the potential treatment of Alzheimer's disease. CNS Drug Rev 1995;1:1-26.
4. Bannon AW, Decker MW, Curzon P, et al. ABT-594 [(R)-5-(2- azetidinylmethoxy)-2-chloropyridine]: A novel orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Ther 1998:285:787-794.
5. Bencherif M. Pharmaceutical compositions for the prevention and treatment of central nervous disorders. US Pat. No. 6.218.383; 2001.
6. Bencherif M, Bane AJ, Miller CH, Dull GM, Gatto GJ. TC-2559: A novel orally active ligand selective at neuronal acetylcholine receptors. Eur J Pharmacol 2000;409:45-55.
7. Bencherif M, Lovette ME, Fowler KW, et al. TC-2403: A nicotinic agonist with CNS selectivity. I. In vitro characterization. J Pharmacol Exp Ther 1996;279:1413-1421.
8. Bencherif M, Schmitt JD. Targeting neuronal nicotinic receptors: A path to new therapies. Curr Drug Target CNS Neurol Disord 2002;1:349-357.
9. Bontempi B, Whelan KT, Risbrough VB, et al. SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]-thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: Effects on working and reference memory performances in aged rodents and nonhuman primates. J Pharmacol Exp Ther 2001;299:297-306.
10. Borlongan CV, Shytle RD, Ross SD, et al. (-)-Nicotine protects against systemic kainic acid-induced excitotoxic effects. Exp Neurol 1995;136:261-265.
11. Brioni JD, Decker MW, Sullivan JP, Arneric SP. The pharmacology of (-)-nicotine and novel cholinergic channel modulators. In: August JT. Anders MW, Murad F, Coyle JT, Eds. Advances in pharmacology. New York: Academic Press, 1997;153-214.
12. Buccafusco JJ, Terry AV. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 2000;295:438-446.
13. Cosford NDP, Bleitcher L, Herbaut A, et al. (S)-(-)-5-Ethynyl-3-(1- methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): A novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem 1996;39:3235-3237.
14. Decker MW, Brioni JD, Sullivan JP, et al. (S)-3-Methyl-5-(1-methyl-2- pyrrolidinyl)isoxazole (ABT-418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther 1994;270:319-328.
15. Donnelly-Roberts DL, Xue IC, Americ SP, Sullivan, JP. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res 1996;719:36-44.
16. 2 receptor upregulation induced by a partial meso-diencephalic hemitransection in the rat. Brain Res 1994;655: 25-32.
17. Jeyarasasingam G, Tompkins L, Quik M. Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4- phenylpyridinium-induced toxicity in culture. Neuroscience 2002; 109:275-285.
18. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing, and short-term memory in Alzheimer's disease. Psychopharmacology 1992;108:485-494.
19. Kaneko S, Maeda T, Kume T, et al. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors. J Brain Res 1997;765:135-140.
20. Kihara T, Shimohama S, Sawada H, et al. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997;42:59-63.
21. 2 nicotinic acetylcholine receptor inhibits β-amyloid toxicity. Brain Res 1998;792:331-334.
22. Levin ED, Nicotinic system and cognitive function. Psychopharmacology 1992;108:485-494.
23. Levin ED, Briggs SJ, Christopher NC. Persistence of chronic-induced cognitive facilitation. Behav Neural Biol 1992;58:152-158.
24. Levin ED, Briggs SJ, Christopher NC, Rose JE. Chronic stimulation and blockade effects on working memory. Behav Pharmacol 1993;4:179-182.
25. Lippiello PM, Bencherif M, Gray JA, et al. TC-2403: A nicotinic agonist with CNS selectivity. I. In vivo characterization. J Pharmacol Exp Ther 1996;279:1422-1429.
26. Lippiello PM, Gatto G, Bencherif M, Caldwell WS. TC-1734: A potent selective nicotinic ligand improves cognition acutely and chronically. Abstr Soc Neurosci 1998;24:88.
27. Marin P, Maus M, Desagher S, Glowinsky J, Premont J. Nicotine protects cultured striatal neurons against N-methyl-D-aspartate receptor-mediated neurotoxicity. Neuroreport 1994;5:1977-1980.
28. Nanri M, Kasahara N, Yamamoto J, Miyake H, Watanabe H. GTS-21, a nicotinic agonist, protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats. Jpn J Pharmacol 1997;74:285-289.
29. Newhouse PA, Sunderland T, Thompson K, et al. Intravenous nicotine in a patient with Alzheimer's disease. Am J Psychiatry 1986;143:1494-1495.
30. Obinu MC, Reibaud M, Miquet JM, Pasquet M, Rooney T. Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:913-918.
31. Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 1989;154: 797-800.
32. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry 1996;35:13568-13578.
33. Schmitt JD, Bencherif M. Targeting nicotinic acetylcholine receptors: Advances in molecular design and therapies. In: Doherty AM, Ed. Annual report in medicinal chemistry. San Diego: Academic Press, 2000; 41-51.
34. Semba J, Miyoshi R, Kito S. Nicotine protects against the dexamethasone potentiation of kainic acid-induced neurotoxicity in cultured hippocampal neurons. Brain Res 1996;735:335-338.
35. Shaw S, M. Bencherif, Marrero MB. Janus kinase 2: An early target of alpha7 nicotinic acetylcholine receptor mediated neuroprotection against Aβ(1-42). J Biol Chem 2002;277:44920-44924.
36. Shimohama S, Akaike A, Kimura J. Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation. Ann NY Acad Sci 1996;77:356-361.
37. Summers KL, Giacobini E. Effects of local and repeated systemic administration of (-)nicotine on extracellular levels of acetylcholine, norepinephrine, dopamine, and serotonin in rat cortex. Neurochem Res 1995; 20:683-689.
38. Summers KL, Lippiello P, Giacobini E. A microdialysis study of the effects of the nicotinic agonist TC-2403 on cortical release of acetylcholine and biogenic amines. Neurochem Res 1996;21:1181-1186.
39. Yamashita H, Nakamura S. Nicotine rescues PC12 cells from death induced by nerve growth factor deprivation. Neurosci Lett 1996;213(2):145-147.